Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | PKM | P14618 | 5/20 | 0.66 |
| ▸ | PKLR | P30613 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.66 |
| ▸ | THRB | P10828 | 1/20 | 0.66 |
| ▸ | CNR1 | P21554 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | IL1RN | P18510 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL396589 | 0.98 | ALDH1A1 (0.69) | ALDH1A1SMN1; SMN2PKMPKLRLMNA | |
| SCHEMBL10860773 | 0.91 | PKM (0.77) | ALDH1A1SMN1; SMN2PKMPKLRLMNA | |
| SCHEMBL2856804 | 0.85 | APOBEC3A (0.67) | PKMPKLRLMNAGAAKMT2A | |
| SCHEMBL2851159 | 0.83 | PKM (0.62) | ALDH1A1SMN1; SMN2PKMPKLRLMNA | |
| SCHEMBL266849 | 0.83 | PKM (0.67) | SMN1; SMN2PKMPKLRLMNATSHR | |
| SCHEMBL6224554 | 0.83 | PKM (0.67) | SMN1; SMN2PKMPKLRLMNATSHR | |
| SCHEMBL856792 | 0.83 | PKM (0.66) | ALDH1A1SMN1; SMN2PKMPKLRLMNA | |
| SCHEMBL30976596 | 0.83 | PKM (0.62) | ALDH1A1SMN1; SMN2PKMPKLRLMNA | |
| SCHEMBL29507905 | 0.83 | PKM (0.66) | ALDH1A1SMN1; SMN2PKMPKLRLMNA | |
| SCHEMBL8982209 | 0.83 | ALDH1A1 (0.72) | ALDH1A1SMN1; SMN2LMNATSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116856016-A | Electroforming solution for platinum electroforming process and preparation method thereof | 深圳市铭轩珠宝首饰有限公司 | 2023-10-10 | — | — | CN | claimed |
| US-12540129-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-12281060-B2 | Remodilins for airway remodeling and organ fibrosis | THE UNIVERSITY OF CHICAGO (US) | 2025-04-22 | — | — | US | disclosed |
| US-20240415851-A1 | REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA | THE UNIVERSITY OF CHICAGO (US) | 2024-12-19 | — | — | US | disclosed |
| CN-116856016-A | Electroforming solution for platinum electroforming process and preparation method thereof | 深圳市铭轩珠宝首饰有限公司 | 2023-10-10 | — | — | CN | disclosed |
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230241074-A1 | INHIBITORS OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS | Atomwise Inc. | 2023-08-03 | — | — | US | disclosed |
| US-20230241074-A1 | INHIBITORS OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS | Atomwise Inc. | 2023-08-03 | — | — | US | disclosed |
| US-20230241074-A1 | INHIBITORS OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS | Atomwise Inc. | 2023-08-03 | — | — | US | disclosed |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2006-04-06 | — | — | US | disclosed |
| EP-1183229-B1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK AS (DK) | 2005-10-26 | — | — | EP | disclosed |
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2005-09-15 | — | — | US | disclosed |
| US-6875760-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2005-04-05 | — | — | US | disclosed |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-11-27 | — | — | US | disclosed |
| US-6638921-B1 | Pharmaceutically acceptable derivatives thereof Cx, R1 and R2 being as defined in the disclosure may be used to inhibit the activity of HIV integrase. | PHARMACOR INC. (CA) | 2003-10-28 | — | — | US | disclosed |
| WO-2003082881-A2 | PYRIDOXAL-5-PHOSPHATE DERIVATIVES AS HIV INTEGRASE INHIBITORS | PROCYON BIOPHARMA INC. (CA) | 2003-10-09 | — | — | WO | disclosed |
| US-6503949-B1 | Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity | NORO NORDISK A/S (DK) | 2003-01-07 | — | — | US | disclosed |
| EP-1183229-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000069810-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | BCL6, SOX18, BCL3 | ALDH1A1 2654/4885SMN1; SMN2 4270/4885PKM 3856/4885 |
| US-20230241074-A1 | INHIBITORS OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS | MAVS, PIGS, SARS1 | ALDH1A1 2721/4885SMN1; SMN2 4762/4885PKM 920/4885 |
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | ALDH1A1 3968/4885SMN1; SMN2 3528/4885PKM 3516/4885 |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | ALDH1A1 3968/4885SMN1; SMN2 3528/4885PKM 3516/4885 |
| US-12540129-B2 | KIF18A inhibitors | KIF18A, KIFC1, KIF2C | ALDH1A1 802/4885SMN1; SMN2 772/4885PKM 1618/4885 |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | CFTR, ABCC4, ABCC2 | ALDH1A1 2221/4885SMN1; SMN2 4740/4885PKM 3024/4885 |
| US-12281060-B2 | Remodilins for airway remodeling and organ fibrosis | MYLK, MFAP1, FIBP | ALDH1A1 3220/4885SMN1; SMN2 4619/4885PKM 4378/4885 |
| US-20240415851-A1 | REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA | HIF1AN, RHOXF2, HIF1A | ALDH1A1 2857/4885SMN1; SMN2 4731/4885PKM 3281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.